SG11202101922YA - Highly versatile method for granting new binding specificity to antibody - Google Patents
Highly versatile method for granting new binding specificity to antibodyInfo
- Publication number
- SG11202101922YA SG11202101922YA SG11202101922YA SG11202101922YA SG11202101922YA SG 11202101922Y A SG11202101922Y A SG 11202101922YA SG 11202101922Y A SG11202101922Y A SG 11202101922YA SG 11202101922Y A SG11202101922Y A SG 11202101922YA SG 11202101922Y A SG11202101922Y A SG 11202101922YA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- binding specificity
- highly versatile
- new binding
- versatile method
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018144345 | 2018-07-31 | ||
PCT/JP2019/030081 WO2020027224A1 (ja) | 2018-07-31 | 2019-07-31 | 新たな結合特異性を抗体に付与する超汎用法 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101922YA true SG11202101922YA (en) | 2021-03-30 |
Family
ID=69231246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101922YA SG11202101922YA (en) | 2018-07-31 | 2019-07-31 | Highly versatile method for granting new binding specificity to antibody |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210317233A1 (ko) |
EP (1) | EP3831846A4 (ko) |
JP (2) | JP7303527B2 (ko) |
KR (1) | KR20210038580A (ko) |
CN (1) | CN112566928A (ko) |
AU (1) | AU2019313945A1 (ko) |
CA (1) | CA3111050A1 (ko) |
EA (1) | EA202190397A1 (ko) |
IL (1) | IL280500A (ko) |
SG (1) | SG11202101922YA (ko) |
WO (1) | WO2020027224A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022009992A1 (ja) * | 2020-07-10 | 2022-01-13 | 国立大学法人東京大学 | 環状ペプチド、ペプチド複合体、並びに、当該環状ペプチド及び/又は当該ペプチド複合体を含む医薬組成物 |
WO2023179370A1 (en) * | 2022-03-21 | 2023-09-28 | The Hong Kong Polytechnic University | Peptidic bispecific antibody, methods for preparation and uses thereof |
WO2024048683A1 (ja) * | 2022-08-30 | 2024-03-07 | ミラバイオロジクス株式会社 | 人工タンパク質及び医薬組成物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180343B1 (en) * | 1998-10-08 | 2001-01-30 | Rigel Pharmaceuticals, Inc. | Green fluorescent protein fusions with random peptides |
WO2001083525A2 (en) | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides, comprising an fc domain, as therapeutic agents |
EA011879B1 (ru) | 2004-09-24 | 2009-06-30 | Эмджин Инк. | МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
AT503902B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
EP2141175B1 (en) | 2007-03-26 | 2016-07-27 | The University of Tokyo | Process for synthesizing cyclic peptide compound |
US20120208720A1 (en) | 2009-10-22 | 2012-08-16 | Kenji Kashiwagi | Rapid display method in translational synthesis of peptide |
US9657289B2 (en) | 2010-12-03 | 2017-05-23 | The University Of Tokyo | Peptide with safer secondary structure, peptide library, and production methods for same |
BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
JP6628966B2 (ja) | 2012-06-14 | 2020-01-15 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
EP2912058A1 (en) * | 2012-10-23 | 2015-09-02 | The Board of Regents of The University of Texas System | Antibodies with engineered igg fc domains |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
JP6754997B2 (ja) | 2013-08-26 | 2020-09-16 | 国立大学法人 東京大学 | 大環状ペプチド、その製造方法、及び大環状ペプチドライブラリを用いるスクリーニング方法 |
CN106589129B (zh) * | 2016-12-30 | 2021-03-05 | 上海近岸生物科技有限公司 | 一种结合cd19、cd3和cd28的三功能分子及其应用 |
KR102357604B1 (ko) * | 2017-07-31 | 2022-02-08 | 도꾜 다이가꾸 | 환상 펩티드를 단백질 구조에 제시시키는 초범용법 |
-
2019
- 2019-07-31 AU AU2019313945A patent/AU2019313945A1/en active Pending
- 2019-07-31 CA CA3111050A patent/CA3111050A1/en active Pending
- 2019-07-31 US US17/264,496 patent/US20210317233A1/en active Pending
- 2019-07-31 KR KR1020217005026A patent/KR20210038580A/ko unknown
- 2019-07-31 EP EP19843928.3A patent/EP3831846A4/en active Pending
- 2019-07-31 EA EA202190397A patent/EA202190397A1/ru unknown
- 2019-07-31 CN CN201980050975.6A patent/CN112566928A/zh active Pending
- 2019-07-31 JP JP2020534722A patent/JP7303527B2/ja active Active
- 2019-07-31 SG SG11202101922YA patent/SG11202101922YA/en unknown
- 2019-07-31 WO PCT/JP2019/030081 patent/WO2020027224A1/ja active Application Filing
-
2021
- 2021-01-28 IL IL280500A patent/IL280500A/en unknown
-
2023
- 2023-04-20 JP JP2023069600A patent/JP2023093637A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EA202190397A1 (ru) | 2021-06-11 |
CN112566928A (zh) | 2021-03-26 |
KR20210038580A (ko) | 2021-04-07 |
WO2020027224A1 (ja) | 2020-02-06 |
CA3111050A1 (en) | 2020-02-06 |
JP7303527B2 (ja) | 2023-07-05 |
US20210317233A1 (en) | 2021-10-14 |
EP3831846A1 (en) | 2021-06-09 |
IL280500A (en) | 2021-03-25 |
JP2023093637A (ja) | 2023-07-04 |
EP3831846A4 (en) | 2022-05-11 |
AU2019313945A1 (en) | 2021-03-18 |
JPWO2020027224A1 (ja) | 2021-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276537A (en) | Antibodies bind to GPRC5D | |
ZA202203250B (en) | Cd3 binding antibodies | |
ZA201808209B (en) | Antibody for binding to interleukin 4 receptor | |
SG11202106214YA (en) | Novel anti-ccr8 antibody | |
IL263840A (en) | cd3 binding antibodies | |
IL287613A (en) | Antibodies that bind gprc5d | |
IL283939A (en) | Antibodies bind to cd3 | |
IL256848A (en) | Antibody molecules that bind cd45 | |
IL256870A (en) | Constructs for bispecific antibodies that bind to CD70 and CD3 and uses thereof | |
IL274370A (en) | Single-region antibodies that bind CD137 | |
EP3294766C0 (en) | HUMANIZED ANTIBODY OR FRAGMENT THEREOF SPECIFIC FOR CD3 | |
HK1250737A1 (zh) | 結合cd79的抗體分子 | |
SG11201709908QA (en) | Method for quantifying monoclonal antibody | |
IL292727A (en) | Multispecific antibodies | |
ZA201907065B (en) | Monoclonal antibody to pd-l1 | |
IL282590A (en) | Heavy chain antibodies that bind to CD38 | |
IL265016B (en) | A method for purifying antibodies | |
IL280500A (en) | A super versatile method to deliver a novel binder with tailored specificity to an antibody | |
SG10201913225SA (en) | Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor | |
GB201811403D0 (en) | Antibody molecules | |
EP3458077A4 (en) | METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING | |
IL269394A (en) | Antibodies bind to STEAP-1 | |
IL292698A (en) | Amino-terminated scfv multispecific binding molecules | |
IL292799A (en) | Antibodies against siglec-9 | |
IL289959A (en) | Antibody purification methods |